Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Collegium Pharmaceutical Inc (COLL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: COLL (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $44.6
1 Year Target Price $44.6
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 51.32% | Avg. Invested days 46 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.21B USD | Price to earnings Ratio 36.18 | 1Y Target Price 44.6 |
Price to earnings Ratio 36.18 | 1Y Target Price 44.6 | ||
Volume (30-day avg) 5 | Beta 0.68 | 52 Weeks Range 23.23 - 42.29 | Updated Date 08/29/2025 |
52 Weeks Range 23.23 - 42.29 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.06 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate 1.66 | Actual 1.68 |
Profitability
Profit Margin 5.13% | Operating Margin (TTM) 20.02% |
Management Effectiveness
Return on Assets (TTM) 7.76% | Return on Equity (TTM) 16.16% |
Valuation
Trailing PE 36.18 | Forward PE 5.45 | Enterprise Value 1815063570 | Price to Sales(TTM) 1.71 |
Enterprise Value 1815063570 | Price to Sales(TTM) 1.71 | ||
Enterprise Value to Revenue 2.57 | Enterprise Value to EBITDA 5.23 | Shares Outstanding 31502100 | Shares Floating 28080681 |
Shares Outstanding 31502100 | Shares Floating 28080681 | ||
Percent Insiders 1.78 | Percent Institutions 116.55 |
Upturn AI SWOT
Collegium Pharmaceutical Inc
Company Overview
History and Background
Collegium Pharmaceutical, Inc. was founded in 2003. Initially focused on pain management, the company has evolved through product development and acquisitions. A significant milestone was the FDA approval of Xtampza ER, an abuse-deterrent opioid. They were acquired by Integra LifeSciences in 2022.
Core Business Areas
- Pain Management: Development and commercialization of pain medications, with a focus on abuse-deterrent formulations. Key product was Xtampza ER before acquisition.
Leadership and Structure
Prior to acquisition by Integra LifeSciences, Collegium had a typical corporate structure with a CEO, CFO, and other executive leadership roles responsible for various departments such as research and development, sales, and marketing.
Top Products and Market Share
Key Offerings
- Xtampza ER: Xtampza ER was an abuse-deterrent extended-release oxycodone product. While exact market share data varies, it competed in the opioid analgesic market against products from Purdue Pharma (OxyContin), Teva Pharmaceutical Industries (generic opioids), and Mallinckrodt. Revenue data prior to acquisition is available in SEC filings.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the pain management sector, is highly regulated and competitive. Trends include the development of abuse-deterrent formulations, increased scrutiny of opioid prescriptions, and growing demand for non-opioid pain relief options.
Positioning
Collegium positioned itself as an innovator in abuse-deterrent opioid technology. This offered a competitive advantage in a market facing pressure to reduce opioid abuse.
Total Addressable Market (TAM)
The opioid analgesic market was valued in the billions. Collegium targeted a segment of this TAM by offering an abuse-deterrent alternative. The TAM size depends on the specific product and the changing regulations around pain medication.
Upturn SWOT Analysis
Strengths
- Abuse-deterrent technology
- FDA-approved product (Xtampza ER)
- Experienced management team (Prior to acquisition)
Weaknesses
- Dependence on a single key product (Xtampza ER)
- Competition from established opioid manufacturers
- Negative public perception of opioids
Opportunities
- Expanding the abuse-deterrent product line
- Partnerships with healthcare providers and advocacy groups
- Developing non-opioid pain management solutions
Threats
- Increased regulatory scrutiny of opioids
- Generic competition
- Product liability lawsuits
- Changing prescribing guidelines
Competitors and Market Share
Key Competitors
- Purdue Pharma (Private)
- Teva Pharmaceutical Industries (TEVA)
- Mallinckrodt (MNK)
Competitive Landscape
Collegium had a competitive advantage with its abuse-deterrent technology but faced competition from larger, more established pharmaceutical companies with broader product portfolios and greater resources.
Major Acquisitions
Integra LifeSciences
- Year: 2022
- Acquisition Price (USD millions): 604
- Strategic Rationale: Integra LifeSciences acquired Collegium to expand its pain management portfolio and leverage Collegium's abuse-deterrent technology.
Growth Trajectory and Initiatives
Historical Growth: Historical growth was driven by the adoption of Xtampza ER in the pain management market. Factors influencing growth included sales force effectiveness, marketing campaigns, and reimbursement rates.
Future Projections: Future projections would depend on Integra LifeSciences' strategy for Xtampza ER and its continued development of abuse-deterrent pain medications.
Recent Initiatives: Recent initiatives prior to acquisition included efforts to expand Xtampza ER's market reach and develop new formulations or delivery methods.
Summary
Collegium Pharmaceutical carved a niche in the pain management market with its abuse-deterrent technology. However, it faced intense competition and regulatory challenges common to the opioid market. Its acquisition by Integra LifeSciences reflects both the potential of its technology and the difficulty of competing as a smaller player in the pharmaceutical industry. Prior to acquisition, revenue was strong for a single product company with limited offerings.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings of Collegium Pharmaceutical prior to acquisition
- Industry reports on the pharmaceutical market
- Press releases and company websites
- Analyst reports
Disclaimers:
The information provided is based on publicly available data and is for informational purposes only. It should not be considered financial advice. Market share data is approximate and may vary based on source. This analysis reflects the company prior to its acquisition by Integra LifeSciences. Private companies cannot be used with ticker symbols.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Collegium Pharmaceutical Inc
Exchange NASDAQ | Headquaters Stoughton, MA, United States | ||
IPO Launch date 2015-05-07 | CEO, President, Executive VP & Director Mr. Vikram Karnani | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 357 | Website https://www.collegiumpharma.com |
Full time employees 357 | Website https://www.collegiumpharma.com | ||
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.